Ohsu Knight Cancer Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.ohsu.edu/knight-cancer-institute

Clinical Trials

Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer

Not Applicable

Completed

Conditions: Dysphagia
Pain
Stage I Oropharyngeal Squamous Cell Carcinoma
Stage II Oropharyngeal Squamous Cell Carcinoma
Stage III Oropharyngeal Squamous Cell Carcinoma

Interventions: Drug: Dexamethasone
Procedure: Quality-of-Life Assessment
Other: Placebo
Other: Questionnaire Administration
Procedure: Transoral Robotic Surgery

First Posted Date: 2012-12-13

Last Posted Date: 2018-06-19

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 76

Registration Number: NCT01748942

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Pathogenesis of Hematologic Malignancies

Conditions: Myelodysplastic Syndromes
Lymphoproliferative Disorders
Acute Leukemia
Myeloproliferative Disorders

Interventions: Procedure: blood draw, bone marrow procedure, or tissue biopsy

First Posted Date: 2012-11-19

Last Posted Date: 2024-03-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 5000

Registration Number: NCT01728402

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Vietnamese Women's Health Project III

Completed

Conditions: Cervical Cancer

Interventions: Other: Demographic Form and Semi-Structured Interview Guide

First Posted Date: 2012-10-11

Last Posted Date: 2020-09-30

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 13

Registration Number: NCT01704235

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Hydroxychloroquine
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sirolimus

First Posted Date: 2012-09-21

Last Posted Date: 2017-09-07

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01689987

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction

Not Applicable

Terminated

Conditions: Breast Cancer
Perioperative/Postoperative Complications

Interventions: Drug: fibrin sealant (Beriplast P, TISSEEL VH)
Procedure: breast reconstruction

First Posted Date: 2012-07-25

Last Posted Date: 2022-11-02

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT01649505

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)

Not Applicable

Completed

Conditions: Postmenopausal
Malignant Neoplasm

Interventions: Behavioral: Exercise Intervention
Other: Questionnaire Administration

First Posted Date: 2012-07-09

Last Posted Date: 2021-09-24

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 444

Registration Number: NCT01635413

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Phase 2

Terminated

Conditions: Recurrent Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Refractory Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Other: Antitumor Drug Screening Assay
Other: Laboratory Biomarker Analysis
Drug: Dasatinib
Drug: Idelalisib
Drug: Pacritinib
Other: Pharmacological Study
Drug: Sunitinib
Drug: Sorafenib
Drug: Ponatinib
Drug: Ruxolitinib
Drug: Sunitinib Malate
Drug: Sorafenib Tosylate
Drug: Ponatinib Hydrochloride

First Posted Date: 2012-06-15

Last Posted Date: 2021-11-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 12

Registration Number: NCT01620216

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis

Completed

Conditions: Melanoma

Interventions: Device: VivaScope System

First Posted Date: 2012-03-16

Last Posted Date: 2016-04-25

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 24

Registration Number: NCT01556503

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Compassionate Use Ponatinib

Conditions: Philadelphia Chromosome Positive (Ph+) Leukemias
Chronic Myeloid Leukemia

First Posted Date: 2012-03-09

Last Posted Date: 2013-03-15

Lead Sponsor: OHSU Knight Cancer Institute

Registration Number: NCT01549548

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

Phase 3

Completed

Conditions: Menopause
Dyspareunia
Vulvodynia
Breast Cancer

Interventions: Drug: Topical liquid lidocaine
Drug: Topical saline

First Posted Date: 2012-02-27

Last Posted Date: 2017-04-14

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 50

Registration Number: NCT01539317

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy